1
|
Li S, Wang W, Li T, Han X, Hu C, Wang Y, Shen M, Du L, Nai Y, Wang J, Jin A. Immune characteristics analysis reveals two key inflammatory factors correlated to the expressions of SARS-CoV-2 S1-specific antibodies. Genes Dis 2020; 9:522-530. [PMID: 33521209 PMCID: PMC7832135 DOI: 10.1016/j.gendis.2020.12.007] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2020] [Accepted: 12/16/2020] [Indexed: 12/18/2022] Open
Abstract
The pandemic of COVID-19 caused by SARS-CoV-2 has made serious threats to the public health. Antibodies have been considered as promising therapeutics for the prevention and treatment of pathogens. So far, effectors that can influence the sustainability of SARS-CoV-2 specific antibodies in COVID-19 patients are still unclear. In this paper, we attempted to find potential key factors correlated with SARS-CoV-2 specific antibodies. Transcriptional analysis with the peripheral blood mononuclear cells (PBMCs) revealed proportional changes of immune cell subsets in COVID-19 convalescent patients, including a substantial decrease of monocytes and evident increase of dendritic cells (DCs). Moreover, we found that the gene expressions of chemokines associated with monocyte/macrophage were significantly up-regulated during the COVID-19 recovery phase. Most importantly, we found a set of 27 immune genes corresponding to a comparatively lower amount of SARS-CoV-2 specific antibodies, and identified two hub genes, IL1β and IL6, the protein expressions of which exhibited negative correlation with the immunoglobulin G (IgG) levels in COVID-19 convalescent sera. In addition, we found that high expressions of these 2 hub genes during the convalescent stage were negatively associated with the plasma cell marker CD138. Our study presented two key inflammatory factors correlated to the low level of SARS-CoV-2 specific antibodies, which indicated the potential regulatory process of plasmatic antibodies levels in some COVID-19 convalescent patients.
Collapse
Affiliation(s)
- Shenglong Li
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.,Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China
| | - Wang Wang
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.,Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China
| | - Tingting Li
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.,Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China
| | - Xiaojian Han
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.,Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China
| | - Chao Hu
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.,Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China
| | - Yingming Wang
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.,Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China
| | - Meiying Shen
- Department of Breast Surgery, Harbin Medical University Cancer Hospital
| | - Li Du
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.,Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China
| | - Yaru Nai
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.,Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China
| | - Jianwei Wang
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.,Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China
| | - Aishun Jin
- Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China.,Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China
| |
Collapse
|
2
|
Kyuregyan KK, Polyakov AD, Potemkin IA, Karlsen AA, Isaeva OV, Lopatukhina MA, Mullin EV, Slukinova OS, Malinnikova EY, Shibrik EV, Oglezneva EE, Mikhailov MI. [Belgorod region - the territory endemic for hepatitis E.]. Vopr Virusol 2019; 64:274-280. [PMID: 32168441 DOI: 10.36233/0507-4088-2019-64-6-274-280] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2019] [Accepted: 12/24/2019] [Indexed: 12/27/2022]
Abstract
INTRODUCTION Belgorod region is the territory with the highest incidence of hepatitis E in the Russian Federation. OBJECTIVES The aim of the study was to comprehensively characterize the circulation of hepatitis E virus (HEV) in the Belgorod region, including the study of population immunity to the virus, determining the prevalence of infection among the pig population and analysis of the genetic diversity of HEV from patients and animals. MATERIAL AND METHODS Serum samples of a conditionally healthy population (n = 2027) of all age groups were tested for anti-HEV IgG and IgM by ELISA with commercial assays. HEV RNA was determined in fecal samples from pigs aged 2-4 months (n = 526), in sewage samples from pig farms (n = 10), as well as in stool samples from patients with hepatitis E (n = 6) using reverse transcription polymerase chain reaction (RT-PCR). Phylogenetic analysis was performed for an amplified 300 nt fragment corresponding to HEV open reading frame 2. RESULTS AND DISCUSSION The prevalence of anti-HEV IgG in general population averaged 16.4% (95% CI: 14.8-18.1; 332/2027). The proportion of individuals who had both anti-HEV IgM and IgG averaged 2.8% (95% CI: 2.2-3.6; 57/2027). The incidence rate of anti-HEV IgG increased with age, from 2.8% (95% CI: 1.3-5.8) in children aged 1-14 years to 40.1% (95% CI: 34.9-45.6) in people 70 years or older. The detection rate of HEV RNA in pigs was 20% (95% CI: 16.8-23.6; 105/526). HEV RNA was detected in 2 out of 10 sewage samples. The HEV sequences isolated from patients with hepatitis E, pigs, and sewage samples in Belgorod region belonged to the HEV genotype 3, had a 95-100% homology, and formed common clusters on a phylogenetic tree. CONCLUSIONS The high prevalence of HEV in pigs population has led to the formation of an endemic territory in the Belgorod region, which is the center of pig breeding. Measures aimed at reducing the circulation of HEV among pig population and decontamination of sewage from pig farms are necessary to control HEV infection.
Collapse
Affiliation(s)
- K K Kyuregyan
- Mechnikov Research Institute for Vaccines and Sera, Moscow, 105064, Russia.,Russian Medical Academy of Continuous Professional Education, Moscow, 125993, Russia
| | - A D Polyakov
- Skolkovo Territorial Division of the Office of Rospotrebnadzor for the City of Moscow Russia, Moscow, 143026, Russia.,Belgorod State National Research University, Belgorod, 308015, Russia
| | - I A Potemkin
- Mechnikov Research Institute for Vaccines and Sera, Moscow, 105064, Russia.,Russian Medical Academy of Continuous Professional Education, Moscow, 125993, Russia
| | - A A Karlsen
- Mechnikov Research Institute for Vaccines and Sera, Moscow, 105064, Russia.,Russian Medical Academy of Continuous Professional Education, Moscow, 125993, Russia
| | - O V Isaeva
- Mechnikov Research Institute for Vaccines and Sera, Moscow, 105064, Russia.,Russian Medical Academy of Continuous Professional Education, Moscow, 125993, Russia
| | - M A Lopatukhina
- Mechnikov Research Institute for Vaccines and Sera, Moscow, 105064, Russia
| | - E V Mullin
- Mechnikov Research Institute for Vaccines and Sera, Moscow, 105064, Russia
| | - O S Slukinova
- Mechnikov Research Institute for Vaccines and Sera, Moscow, 105064, Russia
| | - E Y Malinnikova
- Mechnikov Research Institute for Vaccines and Sera, Moscow, 105064, Russia.,Russian Medical Academy of Continuous Professional Education, Moscow, 125993, Russia
| | - E V Shibrik
- Department of Health and Social Protection of the Population of Belgorod Region, Belgorod, 308005, Russia
| | - E E Oglezneva
- Belgorod State National Research University, Belgorod, 308015, Russia.,Belgorod Regional Department of Rospotrebnadzor, Belgorod, 308023, Russia
| | - M I Mikhailov
- Mechnikov Research Institute for Vaccines and Sera, Moscow, 105064, Russia.,Russian Medical Academy of Continuous Professional Education, Moscow, 125993, Russia
| |
Collapse
|